Connect with us


Medical Marijuana Inc. Records Nearly $21 Million in Revenue for Q2 2019

Phyllis Milka



Medical Marijuana Inc. Records Nearly $21 Million in Revenue for Q2 2019
  • In year-over-year revenue, Medical Marijuana, Inc. experienced over 30% growth.
  • According to the CEO, the second quarter of this year has been the most lucrative in the history of the company.

In the United States, the first publicly traded cannabis company is Medical Marijuana, Inc., and they’ve been an integral part of launching the first-ever cannabis-derived nutraceutical products, brand, and supply chain in the world. Now, according to PR Newswire, the company announced its financial results for Q2 2019, which ended on June 30th, 2019, revealing massive gains.

One of the big changes in this quarter is the record revenue of $20.7 million, which is over 30% higher than what the company brought in during the same quarter last year. From operations, the company generated $1.4 million in profits, achieving a gross profit of $15.4 million during the second quarter. This gross profit is 61% higher than what the company saw last year.

The company decreased in their general and administrative expenses, going from 21% of sales to 16% of sales. While Medical Marijuana experienced a loss of $2 million in this period last year, the net ordinary income for Q2 2019 was $877,964 this year.

Kannaway, a subsidiary of Medical Marijuana, was recognized as a top revenue-generating direct selling company by Direct Selling News and won a Gold Stevie Award for Medium Company of the Year in the Health Products and Services Category. This accolade was given to Kannaway at the 17th Annual American Business Awards.

Speaking on all of this progress, CEO Dr. Stuart Titus of Medical Marijuana, Inc. expressed that the company is “excited” to continue with this upward trajectory of success. He noted that this quart has experience the “largest sales revenue quarter in the history of our Company.” Dr. Titus added that the company aims to remain at the forefront of the market, stating that Arcview Market Research predicts a valuation of $57 billion for the cannabis industry in the next eight years.

Phyllis Milka is one of the newest contributors here at COR and has a diverse, multi-year background with his experienced writing career. Be sure to stay on the lookout for what she is going to help create here.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Join Us On Facebook


Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?